Cosmo Pharmaceuticals N.V. – LSE:0RGI.L
Cosmo Pharmaceuticals N.V. stock price today
Cosmo Pharmaceuticals N.V. stock price monthly change
Cosmo Pharmaceuticals N.V. stock price quarterly change
Cosmo Pharmaceuticals N.V. stock price yearly change
Cosmo Pharmaceuticals N.V. key metrics
Market Cap | 1.01B |
Enterprise value | 1.03B |
P/E | 15.71 |
EV/Sales | 5.57 |
EV/EBITDA | 10.34 |
Price/Sales | 5.86 |
Price/Book | 2.19 |
PEG ratio | -0.47 |
EPS | 0.07 |
Revenue | 96.72M |
EBITDA | 25.77M |
Income | 1.14M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 37.53% |
Oper. margin | 46.38% |
Gross margin | 76.47% |
EBIT margin | 46.38% |
EBITDA margin | 26.65% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeCosmo Pharmaceuticals N.V. stock price history
Cosmo Pharmaceuticals N.V. stock forecast
Cosmo Pharmaceuticals N.V. financial statements
| Mar 2023 | 21.83M | 743K | 3.4% |
|---|---|---|---|
| Jun 2023 | 21.83M | 743K | 3.4% |
| Sep 2023 | 26.53M | -169.5K | -0.64% |
| Dec 2023 | 26.53M | -169.5K | -0.64% |
| 2027 | 355.79M | 165.27M | 46.45% |
|---|
Analysts Price target
Financials & Ratios estimates
| Payout ratio | 6.07% |
|---|
| 2019 | |
|---|---|
| 2020 | |
| 2021 | |
| 2022 | 1.54% |
| 2023 | 1.91% |
| Mar 2023 | 736817000 | 298.65M | 40.53% |
|---|---|---|---|
| Jun 2023 | 736817000 | 298.65M | 40.53% |
| Sep 2023 | 553980000 | 120.34M | 21.72% |
| Dec 2023 | 553980000 | 124.94M | 22.55% |
| Mar 2023 | 7.74M | -28.12M | -13.00M |
|---|---|---|---|
| Jun 2023 | 7.74M | -28.12M | -13.00M |
| Sep 2023 | 9.07M | 48.27M | -91.63M |
| Dec 2023 | 9.07M | 48.27M | -91.63M |
Cosmo Pharmaceuticals N.V. alternative data
| Aug 2023 | 295 |
|---|---|
| Sep 2023 | 319 |
| Oct 2023 | 319 |
| Nov 2023 | 319 |
| Dec 2023 | 319 |
| Jan 2024 | 319 |
| Feb 2024 | 319 |
| Mar 2024 | 319 |
| Apr 2024 | 319 |
| May 2024 | 319 |
| Jun 2024 | 319 |
| Jul 2024 | 325 |
Cosmo Pharmaceuticals N.V. other data
| Insider | Compensation |
|---|---|
Mr. Mauro Severino Ajani Founder & Executive Chairman | |
Mr. Giuseppe Cipriano Chief Operating Officer | |
Mr. Niall Donnelly Chief Financial Officer & Head of Investor Relations | |
Mr. Davide Malavasi Qualified Person & Technical Director | |
Mr. Stefano Selva Chief Scientific Officer | |
Mr. Blake A. Boland Chief Sales Officer | |
Mr. Massimo Pedrani Head of Generics Bus. Devel. | |
Mr. Roberto Villa Chief Manufacturing Officer | |
Mr. Marco Lecchi Head of Internal Audit |
-
What's the price of Cosmo Pharmaceuticals N.V. stock today?
One share of Cosmo Pharmaceuticals N.V. stock can currently be purchased for approximately $66.11.
-
When is Cosmo Pharmaceuticals N.V.'s next earnings date?
Unfortunately, Cosmo Pharmaceuticals N.V.'s (0RGI.L) next earnings date is currently unknown.
-
Does Cosmo Pharmaceuticals N.V. pay dividends?
Yes, Cosmo Pharmaceuticals N.V. pays dividends and its trailing 12-month yield is 5.81% with 6% payout ratio. The last Cosmo Pharmaceuticals N.V. stock dividend of undefined was paid on 6 Sep 2025.
-
How much money does Cosmo Pharmaceuticals N.V. make?
Cosmo Pharmaceuticals N.V. has a market capitalization of 1.01B and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 9.12% to 92.78M US dollars.
-
What is Cosmo Pharmaceuticals N.V.'s stock symbol?
Cosmo Pharmaceuticals N.V. is traded on the LSE under the ticker symbol "0RGI.L".
-
What is Cosmo Pharmaceuticals N.V.'s primary industry?
Company operates in the Healthcare sector and Medical - Pharmaceuticals industry.
-
How do i buy shares of Cosmo Pharmaceuticals N.V.?
Shares of Cosmo Pharmaceuticals N.V. can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Cosmo Pharmaceuticals N.V.'s key executives?
Cosmo Pharmaceuticals N.V.'s management team includes the following people:
- Mr. Mauro Severino Ajani Founder & Executive Chairman
- Mr. Giuseppe Cipriano Chief Operating Officer
- Mr. Niall Donnelly Chief Financial Officer & Head of Investor Relations
- Mr. Davide Malavasi Qualified Person & Technical Director
- Mr. Stefano Selva Chief Scientific Officer
- Mr. Blake A. Boland Chief Sales Officer
- Mr. Massimo Pedrani Head of Generics Bus. Devel.
- Mr. Roberto Villa Chief Manufacturing Officer
- Mr. Marco Lecchi Head of Internal Audit
-
Is Cosmo Pharmaceuticals N.V. founder-led company?
Yes, Cosmo Pharmaceuticals N.V. is a company led by its founder Mr. Mauro Severino Ajani.
-
How many employees does Cosmo Pharmaceuticals N.V. have?
As Jul 2024, Cosmo Pharmaceuticals N.V. employs 325 workers, which is 2% more then previous month and 2% more then previous quarter.
-
When Cosmo Pharmaceuticals N.V. went public?
Cosmo Pharmaceuticals N.V. is publicly traded company for more then 9 years since IPO on 20 May 2016.
-
What is Cosmo Pharmaceuticals N.V.'s official website?
The official website for Cosmo Pharmaceuticals N.V. is cosmopharma.com.
-
How can i contact Cosmo Pharmaceuticals N.V.?
Cosmo Pharmaceuticals N.V. can be reached via phone at +353 1 817 0370.
Cosmo Pharmaceuticals N.V. company profile:
Cosmo Pharmaceuticals N.V.
cosmopharma.comLSE
339
Medical - Pharmaceuticals
Healthcare
Cosmo Pharmaceuticals N.V., a specialty pharmaceutical company, focuses on the development and commercialization products for gastroenterology and endoscopy worldwide. It offers Lialda/Mezavant/Mesavancol and UCERIS/Cortiment, an oral tablet formulation for remission in active, mild to moderate ulcerative colitis; GI Genius, a system that uses artificial intelligence to detect colorectal polyps; and Methylene Blue MMX, diagnostic drug to enhance pre-cancerous and cancerous detection of colorectal lesions during colonoscopy. The company also provides Eleview, an injectable composition for use in gastrointestinal endoscopic procedures for submucosal lift of polyps, adenomas, early-stage cancers, or other gastrointestinal mucosal lesions; Aemcolo/Relafalk, a pharmaceutical product used for the treatment of traveler's diarrhea, uncomplicated acute diverticulitis, minimal hepatic encephalopathy, and small intestine bacterial overgrowth; and Winlevi, an androgen receptor inhibitor for acne vulgaris. In addition, it offers Clascoterone, an androgen receptor inhibitor that targets in the scalp and androgenetic alopecia; Rifamycin for irritable bowel syndrome with diarrhoea; ByFavo (Remimazolam), a fast-acting intravenous benzodiazepine agent for procedural sedation; CB-03-10, an oral androgen receptor antagonist for treatment against solid tumors; CB-01-33 for bile acid diarrhea; and Qolotag, a single use enema formulation. The company has a license agreement with RedHill Biopharma Ltd.; and Acacia Pharma Group plc. Cosmo Pharmaceuticals N.V. was founded in 1997 and is headquartered in Dublin, Ireland.
Dublin, 2
:
ISIN: NL0011832936
:
